Last10K.com

Arch Therapeutics, Inc. (ARTH) SEC Filing 10-K Annual report for the fiscal year ending Saturday, September 30, 2017

SEC Filings

ARTH Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

ARTH Annual Reports

ARTH Quarterly Reports

ARTH Corporate News

ARTH Registration of Securities

Arch Therapeutics, Inc.

HISTORY TOOLS
CIK: 1537561 Ticker: ARTH
Document And Entity Information - USD ($)
12 Months Ended
Sep. 30, 2017
Nov. 14, 2017
Mar. 31, 2017
Document Information [Line Items]   
Document Type10-K  
Amendment Flagfalse  
Document Period End DateSep. 30, 2017  
Document Fiscal Year Focus2017  
Document Fiscal Period FocusFY  
Entity Registrant NameArch Therapeutics, Inc.  
Entity Central Index Key0001537561  
Current Fiscal Year End Date--09-30  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Filer CategorySmaller Reporting Company  
Entity Public Float  $ 78,000,000
Trading SymbolARTH  
Entity Common Stock, Shares Outstanding 153,935,130 

View differences made from one year to another to evaluate Arch Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Arch Therapeutics, Inc..

Continue

Assess how Arch Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Arch Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Stockholders' Equity
Consolidated Statements Of Operations
8% Convertible Notes
8% Convertible Notes (details 1)
8% Convertible Notes (details Textual)
8% Convertible Notes (details)
8% Convertible Notes (tables)
Commitments And Contingencies
Commitments And Contingencies (details Textual)
Commitments And Contingencies (details)
Commitments And Contingencies (tables)
Description Of Business
Income Taxes
Income Taxes (details Textual)
Income Taxes (details)
Income Taxes (tables)
Note Payable
Note Payable (details Textual)
Private Placement Financing 2014
Private Placement Financing 2014 (details Textual)
Private Placement Financing 2015
Private Placement Financing 2015 (details Textual)
Private Placement Financing 2016
Private Placement Financing 2016 (details Textual)
Property And Equipment
Property And Equipment (details Textual)
Property And Equipment (details)
Property And Equipment (tables)
Registered Direct Offering 2017
Registered Direct Offering 2017 (details 1)
Registered Direct Offering 2017 (details Textual)
Registered Direct Offering 2017 (details)
Registered Direct Offering 2017 (tables)
Restricted Stock Awarded Outside The 2013 Stock Incentive Plan
Restricted Stock Awarded Outside The 2013 Stock Incentive Plan (details 1)
Restricted Stock Awarded Outside The 2013 Stock Incentive Plan (details Textual)
Restricted Stock Awarded Outside The 2013 Stock Incentive Plan (details)
Restricted Stock Awarded Outside The 2013 Stock Incentive Plan (tables)
Stock-based Compensation
Stock-based Compensation (details 1)
Stock-based Compensation (details 2)
Stock-based Compensation (details Textual)
Stock-based Compensation (details)
Stock-based Compensation (tables)
Subsequent Events
Subsequent Events (details Textual)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (policies)

Material Contracts, Statements, Certifications & more

Arch Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 23.1: Consents Of Experts And Counsel
Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Ticker: ARTH
CIK: 1537561
Form Type: 10-K Annual Report
Accession Number: 0001144204-17-059213
Submitted to the SEC: Wed Nov 15 2017 7:31:20 AM EST
Accepted by the SEC: Wed Nov 15 2017
Period: Saturday, September 30, 2017
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/arth/0001144204-17-059213.htm